KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $3.8 million.

  • Jazz Pharmaceuticals' Gains from Investment Securities rose 13750.78% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.2 million, marking a year-over-year decrease of 5141.67%. This contributed to the annual value of $57.8 million for FY2024, which is 1334.79% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Gains from Investment Securities stood at $3.8 million, which was up 13750.78% from $2.2 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $105.2 million during Q4 2023, with a 5-year trough of -$91.4 million in Q2 2023.
  • Its 5-year average for Gains from Investment Securities is $13.8 million, with a median of $3.8 million in 2025.
  • The largest annual percentage gain for Jazz Pharmaceuticals' Gains from Investment Securities in the last 5 years was 364293.85% (2023), contrasted with its biggest fall of 155368.1% (2023).
  • Over the past 5 years, Jazz Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $6.0 million in 2021, then tumbled by 53.14% to $2.8 million in 2022, then skyrocketed by 3642.94% to $105.2 million in 2023, then tumbled by 96.19% to $4.0 million in 2024, then decreased by 4.82% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $2.2 million for Q2 2025, and $67.2 million during Q1 2025.